- Profile
- prev
- next
General
-
Headquarters
Boston, Massachusetts, United States
-
Founders & Team
Hector Martinez, Erik Gatenholm, Ariel Kramer
-
Year Founded
2016
-
Number of employees
500
-
Company type
Private company
-
Stock Ticker
STO:CLINK-B
-
Total funding ($M)
4.3
-
Investors
Vinnova, Robert Bosch Venture Capital GmbH
Technical Details
-
Aging Target
Cell Loss
-
Product modality
3D bioprinting, tools
About
CELLINK is a world leading Bioconvergence company, a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.